Pharma channel feed

Af­ter a se­ries of PI3k pile­ups, Genen­tech of­floads a PhII-ready ri­val for fire­sale price

9 years ago
R&D

As­traZeneca R&D leader Pan­ga­los warns of a post-Brex­it UK re­search re­treat with­out re­im­burse­ment re­form

9 years ago

FDA flash­es red light on Sanofi man­u­fac­tur­ing in­frac­tion, threat­en­ing a loom­ing block­buster de­ci­sion

9 years ago

Hu­mana spells out its con­di­tion­al Ex­ondys 51 cov­er­age pol­i­cy — strings at­tached

9 years ago

Au­ven Ther­a­peu­tics sells PhI­II dry eye dis­ease drug to Sun for $40M-plus

9 years ago

No­var­tis promis­es a speedy CAR-T pitch, boasts about its slate of block­busters-to-be

9 years ago
R&D

Why wait? FDA gives ear­ly OK to Mer­ck’s Keytru­da for front­line lung can­cer

9 years ago

FDA clears Glob­al Blood Ther­a­peu­tics to fo­cus on key bio­mark­er in piv­otal sick­le cell tri­al

9 years ago

Kite CEO Arie Bellde­grun preps for a loom­ing date with the FDA as he tack­les first-mover ad­van­tage in CAR-T

9 years ago
People

Clin­ton cam­paign staff: "We have start­ed the war with phar­ma!!"

9 years ago

Pow­er­ful Dems or­ches­trat­ed cam­paign at FDA to pro­vide Bio­gen drug to a dy­ing, high-pro­file fundrais­er

9 years ago

The com­pas­sion­ate use poll: A lop­sided vote fa­vors post­ing poli­cies, with plen­ty of fret­ting

9 years ago

Say what? Com­pas­sion­ate use pro­gram? What com­pas­sion­ate use pro­gram?

9 years ago

The Sarep­ta dilem­ma: Bioethics ex­pert Arthur Ca­plan says it’s time to re­think how to reg­u­late com­pas­sion

9 years ago
People

Take­da adds a $790M dis­cov­ery deal to an on­go­ing R&D over­haul

9 years ago
R&D

Pfiz­er plots a big move (but it's not go­ing very far)

9 years ago

Te­va hands Cell­tri­on $160M to grab US rights on two biosim­i­lars of Roche block­busters

9 years ago
R&D

Feds help NewLink, Mer­ck out with some added cash for Ebo­la vac­cine

9 years ago
R&D

Hold the ap­plause: Big Phar­ma has lit­tle to brag about re­gard­ing 2016 R&D pro­duc­tiv­i­ty

9 years ago
R&D

No­var­tis un­veils a new glob­al R&D struc­ture, cre­at­ing cen­ters in Cam­bridge, MA and Basel

9 years ago
R&D

No­var­tis is up­root­ing an­oth­er re­search group in on­go­ing glob­al re­or­ga­ni­za­tion

9 years ago
R&D

Am­gen joins a mar­quee list of part­ners jump­ing on Nuevo­lu­tion’s dis­cov­ery plat­form

9 years ago
R&D

Mer­ri­mack CEO is out as the biotech re­struc­tures, chop­ping its work­force and over­haul­ing R&D

9 years ago
R&D

As­traZeneca hands off an­oth­er Am­gen-part­nered drug in a $1.5B deal with an ac­quis­i­tive Al­ler­gan

9 years ago
R&D
First page Previous page 339340341342343344345 Next page Last page
A service from the Financial Times